margetuximab + tebotelimab + chemotherapy

Combination therapy consisting of **margetuximab** (a HER2-targeting, Fc-engineered monoclonal antibody), **tebotelimab** (a bispecific DART protein targeting both PD-1 and LAG-3 immune checkpoint pathways), and **chemotherapy** (CTX, investigator’s choice such as XELOX or mFOLFOX-6). **Margetuximab** enhances antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-positive tumor cells by increased activation of effector immune cells, particularly NK cells. **Tebotelimab** blocks both PD-1 and LAG-3 on T-cells, overcoming immune checkpoint-mediated suppression and enhancing T-cell mediated antitumor immunity. Chemotherapy provides cytotoxic effects, potentially increasing antigen release and enabling immune-mediated tumor control. This combination is being evaluated primarily in advanced or metastatic HER2-positive gastroesophageal junction and gastric cancers, among other HER2-positive tumors, for its synergistic dual immunomodulation and cytotoxic activity[1][3][2].

Other names

margetuximab + tebotelimab + CTX